What changed between these versions
A substantive modification. v2 significantly alters the guidance requirements for the Secretary of Health and Human Services from mandatory with specific timelines to discretionary authority. It also includes several technical and clarifying amendments to the biosimilar interchangeability provisions and conforming amendments.
Overview
A handful of substantive changes and several technical corrections. · v2 narrows the mandatory requirements for the Secretary regarding guidance issuance, while clarifying and slightly refining the language around biosimilar interchangeability and conforming amendments.
The most significant change in v2 is the alteration of the Secretary's obligation to issue and update guidance on biosimilar products from a mandatory requirement with strict timelines to a discretionary authority. Additionally, v2 refines the language concerning the timing of deemed interchangeability for biosimilar products, consolidating and clarifying the conditions under which a product is considered interchangeable. Several minor technical corrections, including updates to cross-references and formatting, are also introduced.
Major additions
This new subclause adds a specific cross-reference correction within the amended Section 351(k)(2)(A)(i)(II) of the Public Health Service Act, changing 'item (aa) or (cc)' to 'subclause (I) or (III)'.
This is a technical correction that ensures internal consistency within the newly renumbered and reorganized paragraphs of the Public Health Service Act, preventing potential misinterpretation of references. It does not alter policy.
This new subclause mandates striking 'publicly-available' and inserting 'publicly available' each place it appears within Section 351(k)(2)(C) of the Public Health Service Act.
This is a minor formatting correction to ensure consistent hyphenation, improving readability and adherence to style guides without changing the substantive meaning.
This new subclause amends Section 351(l)(1)(F) of the Public Health Service Act to strike 'publicly-available' and insert 'publicly available'.
Similar to the previous point, this is a minor formatting correction for consistent hyphenation, enhancing readability without substantive policy impact.
Deletions
v1 mandated the Secretary to (1) update existing draft and final guidance documents related to interchangeability within 18 months, (2) issue or revise guidance on biosimilar review and approval within 18 months, and (3) issue revised draft or final versions of such guidances within 18 months after the comment period closes.
The deletion of these specific mandates and timelines removes the strict obligation and deadlines for the Secretary to issue and update guidance documents concerning biosimilar and interchangeable biological products. This shifts the process from a required, time-bound activity to a discretionary one, potentially slowing down or altering the priority of guidance development.
Modifications
This modification improves the clarity and readability of the conditions under which a biosimilar product is deemed interchangeable with its reference product. It does not appear to change the underlying policy regarding the timing or conditions of interchangeability but makes the legal text more efficient and less redundant.
Before
v1 detailed the timing of deemed interchangeability in two separate clauses: one for products licensed on or after the transition date, and another for products licensed prior to the transition date, each with conditions regarding existing exclusivity periods.
After
v2 consolidates these two clauses into a single, more concise paragraph. It states that a biological product is deemed interchangeable upon licensure (or on the transition date if licensed before it), unless it relied on the same reference product as another biological product with an unexpired first interchangeable exclusivity period in effect on the relevant date.
This change ensures precise legal interpretation of when the exclusivity period is considered 'in effect' for the purpose of determining deemed interchangeability, preventing potential ambiguity for products licensed around the enactment date. It does not alter the duration or existence of the exclusivity itself.
Before
v1 stated that for biological products licensed before the Act's enactment, any unexpired first interchangeable exclusivity period would remain in effect for its duration.
After
v2 retains the same core provision but clarifies the reference to the exclusivity period in the context of Section 2(a)(4)(B)(ii) by specifying 'as in effect on the day before the date of enactment of the Biosimilar Red Tape Elimination Act.'
This modification clarifies that the 'new active ingredient' determination under 505B applies not only to initial applications but also to supplements. It also refines the reference to pediatric assessments and the scope of the assessment/investigation, ensuring that pediatric study requirements are consistently applied to biosimilar products and their supplements.
Before
v1 specified that a biological product for which an application is submitted under section 351(k) of the Public Health Service Act shall not be considered to have a new active ingredient for purposes of section 505B(l) unless the application seeks licensure for a pediatric indication or deferral, and the assessment would not involve a product that could not be licensed under 351(k).
After
v2 modifies this by adding 'including a supplement to an application' to the initial clause, changing 'paragraph (4)' to 'subsection (a)(4)' for the pediatric assessment deferral, and replacing 'the assessment' with 'the assessment or investigation described in subsection (a)' in the second condition. It also uses 'such section 351(k)' for brevity.
This change provides the Secretary with greater flexibility in managing guidance documents for biosimilar products. It removes the pressure of strict deadlines and specific content requirements, potentially allowing for a more adaptive approach to guidance but also removing a legislative push for timely updates. It also explicitly protects the application review process from being stalled by guidance delays.
Before
v1 mandated the Secretary to update existing guidance and issue new guidance on biosimilar review and approval within 18 months, with a further mandate to issue revised versions after the comment period.
After
v2 changes this to state that the Secretary 'may issue or revise guidance, as appropriate,' regarding data and information for biosimilarity determinations, including for combination products. It explicitly states that the issuance or non-issuance of such guidance shall not preclude application review or action.
Scope
Meaningful expansion or narrowing — Changes are scattered throughout Section 2, affecting both the core biosimilar interchangeability provisions and the conforming amendments, with a significant alteration to the guidance section. — v2 represents a meaningful shift in the policy direction regarding the mandatory nature and timelines for the Secretary's issuance of guidance on biosimilar products, moving from a prescriptive approach to a discretionary one. Other changes are primarily clarifications and technical corrections. — The technical corrections to cross-references and hyphenation ensure better interaction and consistency with existing statutory language. The change to the guidance provision alters the administrative framework for how biosimilar policy is communicated and implemented by the FDA.
Impact analysis
The Secretary of Health and Human Services (and by extension, the FDA)
Gains flexibility and discretion; loses a legislative mandate for specific actions and timelines.
v1 imposed mandatory duties and strict timelines for issuing and updating guidance on biosimilar and interchangeable products. v2 removes these mandates, granting the Secretary discretion.
Applicants for biosimilar biological products
Experiences a procedural change; potential for less predictable guidance but assurance that application processing won't be halted by lack of guidance.
v1 implied a more predictable schedule for the issuance of FDA guidance, which could inform application strategies. v2 removes this predictability but explicitly states that the absence of guidance will not preclude application review.
Healthcare providers and pharmacists (who rely on interchangeability designations)
Experiences a clarification in the legal framework, potentially leading to more consistent understanding and application of interchangeability rules.
The clarification of the 'Timing of deemed interchangeability' in Section 2(a)(4)(B) provides clearer statutory language regarding when a biosimilar product is considered interchangeable.